NCT05858632 Immune Spatial Features of Guselkumab Cutaneous Response
| NCT ID | NCT05858632 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Psoriasis of Scalp |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 10 participants in total. It began in 2023-07-01 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Eligibility Criteria
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12 Exclusion Criteria: 1. taking systemic immunosuppressives in the last 4 weeks 2. pregnancy 3. severe immunodeficiency (either from genetic or infectious causes). 4. tuberculosis or other active serious infection 5. active systemic malignancy. 6. breast-feeding 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 8. Males who are trying to conceive \-
Contact & Investigator
Raymond Cho, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05858632 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis of Scalp. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05858632 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05858632 currently recruiting?
Yes, NCT05858632 is actively recruiting participants. Contact the research team at rashes@ucsf.edu for enrollment information.
Where is the NCT05858632 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT05858632 clinical trial?
NCT05858632 is sponsored by University of California, San Francisco. The principal investigator is Raymond Cho, MD, PhD at University of California, San Francisco. The trial plans to enroll 10 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.